DA-9601, Artemisia asiatica herbal extract, ameliorates airway inflammation of allergic asthma in mice.
We previously reported that DA-9601, ethanol herbal extract of Artemisia asiatica, inhibited histamine and leukotriene releases in guinea pig lung mast cells activated with specific antigen/antibody reaction. This study aimed to evaluate the inhibitory effect of DA-9601 on the OVA-induced airway inflammation in allergic asthma mouse model. BALB/c mice were sensitized and challenged with OVA. DA-9601 was administered orally 1 h before every local OVA-challenge. OVA-specific serum IgE was measured by ELISA, recruitment of inflammatory cells in BAL fluids and lung tissues by Diff-Quik and H&E staining, respectively, the expressions of CD40, CD40L and VCAM-1 by immunohistochemistry, goblet cell hyperplasia by PAS staining, activities of MMPs by gelatin zymography, expressions of mRNA and proteins of cytokines by RT-PCR and ELISA, activities of MAP kinases by western blot, and activity of NF-KappaB by EMSA. DA-9601 reduced IgE level, recruitment of inflammatory cells into the BAL fluid and lung tissues, expressions of CD40, CD40L and VCAM-1 molecules, goblet cell hyperplasia, MMPs activity, expressions of mRNA and productions of various cytokines, activities of MAP kinases and NK-KappaB increased from OVA-challenged mice. These data suggest that DA-9601 may be developed as a clinical therapeutic agent in allergic diseases due to suppressing the airway allergic inflammation via regulation of various cellular molecules expressed by MAP kinases/NF-KappaB pathway.
Kim
Ji Young
JY
Department of Pharmacology, Sungkyunkwan University School of Medicine, Suwon 440-746, Korea.
Kim
Dae Yong
DY
Lee
Yun Song
YS
Lee
Bong Ki
BK
Lee
Kyung-Hoon
KH
Ro
Jai Youl
JY
D000284:Administration, Oral; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D019306:Artemisia / Q000737:chemistry*; D001249:Asthma / Q000139:chemically induced / Q000188:drug therapy*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D019013:CD40 Antigens / Q000096:biosynthesis; D023201:CD40 Ligand / Q000096:biosynthesis; D016207:Cytokines / Q000096:biosynthesis; D048049:Extracellular Signal-Regulated MAP Kinases / Q000096:biosynthesis; D005260:Female; D008168:Lung / Q000378:metabolism / Q000473:pathology; D048670:MAP Kinase Kinase 4 / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D016328:NF-kappa B / Q000096:biosynthesis; D010047:Ovalbumin; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology*; D019010:Vascular Cell Adhesion Molecule-1 / Q000096:biosynthesis
D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D019013:CD40 Antigens; D016207:Cytokines; C116959:DA 9601; D016328:NF-kappa B; D010936:Plant Extracts; D019010:Vascular Cell Adhesion Molecule-1; D023201:CD40 Ligand; D010047:Ovalbumin; D048049:Extracellular Signal-Regulated MAP Kinases; D048670:MAP Kinase Kinase 4